| |
| |
 |
| |
|
|
| |
An increasing number of diseases are now recognized as being driven by inflammatory processes, and consequently involve various cells of the immune system. These cells include macrophages, microglial cells, T-cells, B-cells, monocytes and mast cells. Plexxikon is developing novel agents that target a number of these cells to address unmet medical needs in rheumatoid arthritis, systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD) and osteoporosis.
Plexxikon is developing an agent that inhibits macrophages, osteoclasts and mast cells by targeting Fms, with varying degrees of Kit inhibition, for the treatment of rheumatoid arthritis. As demonstrated in preclinical studies, this compound is expected to address inflammation and bone erosion, as well as modulate the resultant pain.
 Inflammation: Rheumatoid Arthritis Program Fact Sheet |
|
| |
|
|
|
|
| |
| | | | | | |
| | | | | | | | |
| © 2007 Plexxikon Inc. | Site design by |
| |
|
|
